Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) Director Sarah Kathryn Rouan acquired 1,240 shares of the business's stock in a transaction on Monday, March 31st. The stock was acquired at an average cost of $24.15 per share, for a total transaction of $29,946.00. Following the transaction, the director now owns 1,240 shares of the company's stock, valued at approximately $29,946. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Viking Therapeutics Stock Performance
Shares of VKTX opened at $25.68 on Thursday. The stock has a market capitalization of $2.88 billion, a price-to-earnings ratio of -25.68 and a beta of 0.84. Viking Therapeutics, Inc. has a 52-week low of $23.27 and a 52-week high of $81.86. The stock's 50-day simple moving average is $29.77 and its 200 day simple moving average is $45.78.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.05). During the same quarter in the prior year, the company posted ($0.25) EPS. On average, research analysts forecast that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the company. Blue Trust Inc. raised its position in shares of Viking Therapeutics by 75.9% in the fourth quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock worth $29,000 after buying an additional 309 shares in the last quarter. YANKCOM Partnership purchased a new stake in shares of Viking Therapeutics in the 4th quarter valued at about $33,000. FIL Ltd boosted its position in shares of Viking Therapeutics by 116.8% during the 4th quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 648 shares during the last quarter. CIBC Private Wealth Group LLC grew its holdings in shares of Viking Therapeutics by 170.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 851 shares in the last quarter. Finally, Kapitalo Investimentos Ltda purchased a new stake in Viking Therapeutics in the fourth quarter valued at approximately $63,000. 76.03% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages recently weighed in on VKTX. Scotiabank began coverage on shares of Viking Therapeutics in a report on Thursday, February 13th. They issued a "sector outperform" rating and a $102.00 price target on the stock. Citigroup initiated coverage on shares of Viking Therapeutics in a research note on Friday, February 7th. They issued a "neutral" rating and a $38.00 target price on the stock. Raymond James raised their price target on shares of Viking Therapeutics from $122.00 to $125.00 and gave the stock a "strong-buy" rating in a research note on Thursday, February 6th. Piper Sandler lowered their price target on shares of Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating on the stock in a report on Thursday, February 6th. Finally, B. Riley reissued a "buy" rating and set a $96.00 price objective (down from $109.00) on shares of Viking Therapeutics in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $95.18.
Read Our Latest Stock Report on Viking Therapeutics
Viking Therapeutics Company Profile
(
Get Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
